A5068302103- Atrial Fibrillation Management and Outcomes
- Venous Thromboembolism Diagnosis and Management
- Antiplatelet Therapy and Cardiovascular Diseases
- Lipoproteins and Cardiovascular Health
- Acute Myocardial Infarction Research
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Coronary Interventions and Diagnostics
- Cardiac Imaging and Diagnostics
- Heart Failure Treatment and Management
- Blood Coagulation and Thrombosis Mechanisms
- Cardiac, Anesthesia and Surgical Outcomes
- Peripheral Artery Disease Management
- Diabetes Treatment and Management
- Health Systems, Economic Evaluations, Quality of Life
- Cardiac Arrhythmias and Treatments
- Cancer, Lipids, and Metabolism
- Cardiovascular Function and Risk Factors
- Organ Donation and Transplantation
- Acute Ischemic Stroke Management
- Cardiovascular Health and Disease Prevention
- Renal and Vascular Pathologies
- Adipokines, Inflammation, and Metabolic Diseases
- Blood Pressure and Hypertension Studies
- Cardiac Arrest and Resuscitation
- Cardiac Health and Mental Health
Harvard University
2015-2024
Beth Israel Deaconess Medical Center
2015-2024
Université Paris Cité
2016-2024
Radboud University Medical Center
2024
Brigham and Women's Hospital
2016-2024
Radboud University Nijmegen
2024
Hôpital Bichat-Claude-Bernard
2016-2024
Inserm
2016-2024
Cornell University
2024
Baim Institute for Clinical Research
2021-2024
In patients with atrial fibrillation undergoing percutaneous coronary intervention (PCI) placement of stents, standard anticoagulation a vitamin K antagonist plus dual antiplatelet therapy (DAPT) P2Y12 inhibitor and aspirin reduces the risk thrombosis stroke but increases bleeding. The effectiveness safety rivaroxaban either one or two agents are uncertain.We randomly assigned 2124 participants nonvalvular who had undergone PCI stenting to receive, in 1:1:1 ratio, low-dose (15 mg once daily)...
Human or recombinant apolipoprotein A-I (apoA-I) has been shown to increase high-density lipoprotein-mediated cholesterol efflux capacity and regress atherosclerotic disease in animal clinical studies. CSL112 is an infusible, plasma-derived apoA-I that studied normal subjects those with stable coronary artery disease. This study aimed characterize the safety, tolerability, pharmacokinetics, pharmacodynamics of patients a recent acute myocardial infarction.The AEGIS-I trial (Apo-I Event...
Cardiovascular events frequently recur after acute myocardial infarction, and low cholesterol efflux - a process mediated by apolipoprotein A1, which is the main protein in high-density lipoprotein has been associated with an increased risk of cardiovascular events. CSL112 human A1 derived from plasma that increases capacity. Whether infusions can reduce recurrent infarction unclear.
The AEGIS-II trial hypothesized that CSL112, an intravenous formulation of human apoA-I, would lower the risk plaque disruption, decreasing recurrent events such as myocardial infarction (MI) among high-risk patients with MI. This exploratory analysis evaluates effect CSL112 therapy on incidence CV death and was international, multicenter, randomized, double-blind, placebo-controlled randomized 18,219 acute MI to 4 weekly infusions apoA-I (6g CSL112) or placebo. composite cardiovascular type...
Among patients with ST-elevation myocardial infarction (STEMI), reperfusion injury contributes to additional damage. MTP-131 is a cell-permeable peptide that preserves the integrity of cardiolipin, enhances mitochondrial energetics, and improves myocyte survival during reperfusion. EMBRACE STEMI multicentre, randomized, double-blind Phase 2a trial evaluated efficacy safety vs. placebo infused at rate 0.05 mg/kg/h for 1 h among first-time anterior subjects undergoing primary percutaneous...
Background The IMPROVE score is a validated venous thromboembolism (VTE) assessment tool to risk stratify hospitalized, medically ill patients based on clinical variables. It was hypothesized that addition of D-dimer measurement derive new IMPROVEDD would improve identification at VTE. Methods association the and ≥ 2 × upper limit normal (ULN) with symptomatic deep vein thrombosis, nonfatal pulmonary embolism, or VTE-related death evaluated in 7,441 randomized APEX trial. Based Cox...
Patients with atrial fibrillation who undergo intracoronary stenting traditionally are treated a vitamin K antagonist (VKA) plus dual antiplatelet therapy (DAPT), yet this treatment leads to high risks of bleeding. We hypothesized that regimen rivaroxaban P2Y12 inhibitor monotherapy or DAPT could reduce bleeding and thereby have favorable impact on all-cause mortality the need for rehospitalization.Stented subjects nonvalvular (n=2124) were randomized 1:1:1 administration reduced-dose 15 mg...
Drug-coated balloons (DCBs) are specialized coronary devices comprised of a semicompliant balloon catheter with an engineered coating that allows the delivery antiproliferative agents locally to vessel wall during percutaneous intervention. Although DCBs were initially developed more than decade ago, their potential in interventions has recently sparked renewed interest, especially United States. Originally designed overcome limitations conventional angioplasty and stenting, they aim match...
In the AEGIS-II trial (NCT03473223), CSL112, a human apolipoprotein A1 derived from plasma that increases cholesterol efflux capacity, did not significantly reduce risk of primary endpoint through 90 days versus placebo after acute myocardial infarction (MI). Nevertheless, given well-established relationship between higher low-density lipoprotein (LDL-C) and plaque burden, as well greater reductions seen with PCSK9 inhibitors in patients baseline LDL-C ≥100 mg/dL on statin therapy, efficacy...
Stroke is a morbid and potentially mortal complication among patients hospitalized with acute medical illness. The potential of extended-duration thromboprophylaxis the factor Xa inhibitor betrixaban to reduce risk stroke compared standard-dose enoxaparin in this population was assessed retrospective APEX trial substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban).Hospitalized acutely medically ill subjects (n=7513) were randomized double-dummy...
Background Stent thrombosis (ST) is an uncommon but serious complication of stent implantation. This study aimed to explore factors associated with early, late, and very late ST help guide risk assessment clinical decision-making on ST. Methods The analysis included patients who received placement for the index acute coronary syndrome (ACS). Cumulative incidence was assessed at 30 days (early ST), 31–360 (late 361–720 (very up 720 days. Cox proportional hazards models were used assess...
Asymptomatic deep vein thrombosis (DVT) diagnosed with compression ultrasound (CUS) is a common endpoint in trials assessing the efficacy of anticoagulants to prevent venous thromboembolism (VTE), but relationship asymptomatic thrombus mortality remains uncertain. In APEX trial (ClinicalTrials.gov: NCT01583218), 7,513 acutely ill hospitalized medical patients were randomly assigned extended-duration betrixaban (35-42 days) or enoxaparin (10 ± 4 days). DVT was assessed once CUS between day 32...
Background Extended‐duration betrixaban showed a significant reduction in venous thromboembolism the APEX trial (Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study). Given variable clinical impact of different efficacy and safety events, one approach to assess net outcomes is include only those events that are either fatal or cause irreversible harm. Methods Results This was post hoc analysis trial—a multicenter, double‐blind, randomized controlled comparing...